Filing Details
- Accession Number:
- 0001161697-23-000163
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-16 09:01:06
- Reporting Period:
- 2023-03-15
- Accepted Time:
- 2023-03-16 09:01:06
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1074828 | Know Labs Inc. | KNWN | Measuring & Controlling Devices, Nec (3829) | 900273142 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1931209 | Mouta Leonardo Trautwein | 500 Union Street Suite 810 Seattle WA 98101 | Chief Marketing Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-15 | 6,000 | $0.84 | 19,980 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | $2.04 | 2026-02-04 | 200,000 | 200,000 | Direct | |
Common Stock | Option to Purchase Common Stock | $2.35 | 2026-02-09 | 100,000 | 100,000 | Direct | |
Common Stock | Option to Purchase Common Stock | $2.09 | 2026-12-16 | 100,000 | 100,000 | Direct | |
Common Stock | Option to Purchase Common Stock | $1.48 | 2027-05-20 | 600,000 | 600,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2026-02-04 | 200,000 | 200,000 | Direct |
2026-02-09 | 100,000 | 100,000 | Direct |
2026-12-16 | 100,000 | 100,000 | Direct |
2027-05-20 | 600,000 | 600,000 | Direct |
Footnotes
- Options vest quarterly over four years. No vesting during first 6 months.
- Options vest upon FDA approval
- Options vest quarterly over four years.